India’s drug regulator has given Hetero Labs the green light to manufacture and market its generic version of Gilead Science’s experimental COVID-19 treatment remdesivir, the Indian pharmaceutical company said on Sunday. The drug, which will be marketed under the brand name Covifor, will likely be priced at 5,000 to 6,000 rupees ($66-$79) for a 100 milligram dose, Hetero said.